Autoimmune Diseases  >>  fletikumab (NNC109-0012)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fletikumab (NNC109-0012) / Novo Nordisk
NCT00818064: Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

Completed
1
32
Europe
anti-IL-20, NN8226, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis, Healthy
01/10
01/10
NCT01038674: Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Completed
1
16
Europe
anti-IL-20, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
12/10
12/10

Download Options